Comment
doi: 10.1016/j.eururo.2020.07.034.
Epub 2020 Aug 21.
Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96
Affiliations
- PMID: 32838997
- DOI: 10.1016/j.eururo.2020.07.034
Item in Clipboard
Comment
Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96
Eur Urol.
2020 Nov.
No abstract available
Comment on
-
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
-
Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.Eur Urol. 2020 Nov;78(5):e195. doi: 10.1016/j.eururo.2020.07.030. Epub 2020 Aug 28. Eur Urol. 2020. PMID: 32863056 No abstract available.
Similar articles
-
Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.Eur Urol. 2020 Nov;78(5):e195. doi: 10.1016/j.eururo.2020.07.030. Epub 2020 Aug 28. Eur Urol. 2020. PMID: 32863056 No abstract available.
-
Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.Eur Urol. 2021 Sep;80(3):386. doi: 10.1016/j.eururo.2021.05.027. Epub 2021 Jun 3. Eur Urol. 2021. PMID: 34092438 No abstract available.
-
Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer.Eur Urol. 2020 Aug;78(2):193-194. doi: 10.1016/j.eururo.2020.03.053. Epub 2020 Apr 25. Eur Urol. 2020. PMID: 32345524 No abstract available.
-
Relugolix in the management of prostate cancer.Expert Rev Anticancer Ther. 2022 Sep;22(9):891-902. doi: 10.1080/14737140.2022.2105209. Epub 2022 Jul 27. Expert Rev Anticancer Ther. 2022. PMID: 35866612 Review.
-
Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.Oncology (Williston Park). 2018 Dec 17;32(12):599-602, 604-6. Oncology (Williston Park). 2018. PMID: 30632129 Review.
Cited by
-
Therapeutic effects of an oral gonadotropin-releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF.Reprod Med Biol. 2021 Oct 19;21(1):e12422. doi: 10.1002/rmb2.12422. eCollection 2022 Jan. Reprod Med Biol. 2021. PMID: 34938146 Free PMC article.
-
Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer.Ther Adv Med Oncol. 2021 Mar 24;13:1758835921998586. doi: 10.1177/1758835921998586. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34408793 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
